Ключевые слова
Аннотация
Nonspecific aortoarteritis is a chronic inflammatory disease affecting the aorta and its major branches, leading to progressive vascular damage and complications.
Traditional therapies, including corticosteroids and immunosuppressants, often provide incomplete disease control and carry significant long-term risks. Biological agents have emerged as targeted therapies that inhibit key pro-inflammatory cytokines, effectively reducing disease activity, preventing vascular remodeling, and improving patient quality of life. This paper reviews the pathogenesis of nonspecific aortoarteritis, the clinical applications and efficacy of biologic therapies, and future perspectives in research and treatment. The growing evidence highlights the essential role of biologics in modern management strategies for this condition.
Библиографические ссылки
Nakaoka, Y., et al. Long-term outcomes in Takayasu arteritis patients treated with biologic therapy. Arthritis & Rheumatology. 2015;67:398–409.
Hellmich, B., Agueda, A., Monti, S., et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Annals of the Rheumatic Diseases. 2020;79:19–30.
Hellmich, B., Agueda, A., Monti, S., et al. (2020). 2018 update of the EULAR recommendations for the management of large vessel vasculitis. Annals of the Rheumatic Diseases, 79(1), 19–30.
Matsuura, S., Ohigashi, H., & Yamada, H. (2017). Imaging modalities for disease activity in Takayasu arteritis. Modern Rheumatology, 27(2), 221–230.
Nakaoka, Y., Nakajima, H., & Numano, F. (2015). Long-term outcomes in Takayasu arteritis patients treated with biologic therapy. Arthritis & Rheumatology, 67(2), 398–409.